New combo pill may help diabetes patients control blood sugar
NCT ID NCT06495281
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed observational study looked at over 2,000 adults with type 2 diabetes who were already taking metformin plus another diabetes drug. Researchers wanted to see if adding a new combination pill called Zemidapa (which contains two diabetes medicines) could improve blood sugar control. The main goal was to measure changes in HbA1c (a long-term blood sugar marker) after 12 weeks. The study also tracked how many patients reached the recommended HbA1c target of below 7%.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Zemidapa (a combination of gemigliptin and dapagliflozin) and metformin
What this could lead to
If successful, this could confirm that adding Zemidapa to existing metformin therapy helps more patients reach their blood sugar targets.
What could go wrong
This is an observational study, not a controlled trial, so results may be less reliable. It only looks at short-term (12-week) effects, and long-term benefits or risks remain unknown.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Chonnam National University Hwasun Hospital
Hwasun, Jeollanam-do, 58128, South Korea